BU-NOT-SET

CONTACT US
Explore Recipharm's Full Service Offering
  • Corporate
Recipharm_packaging
Brochure
Successful drug development
  • Drug product
Eyes
Insight
How CDMOs can help reduce the risk of counterfeit medicines entering the supply chain
  • Manufacturing
Eyes
Insight
Tackling complexity in scale-up
  • Drug product
Lab equipment
Insight
Navigating COVID-19 – the role of CDMOs
  • Industry trends
Eyes
Insight
Best pharmaceutical dosage forms
  • Drug product
Production line
Insight
Taking an innovative approach to analytical chemistry
  • Analytical chemistry
Eyes
Insight
Recipharm and Oncopeptides collaborate in the development of Melflufen for the treatment of multiple myeloma
  • Analytical chemistry
Eyes
Insight
Excipients for orally disintegrating products
  • Drug product
Eyes
Insight
Insight
  • Industry trends
Global expansion in the CDMO field
Fact sheet
  • Drug product
Fixed dose combinations - for improved patient compliance
Insight
  • Industry trends
The current state of contract manufacturing
Insight
  • Industry trends
The potential impact of Brexit on patient safety
Insight
  • Manufacturing
EU FMD: After the deadline
Insight
  • Manufacturing
The importance of supply chain security
Insight
  • Drug substance
ADC development: setbacks and key developments
Insight
  • Drug substance
Cytotoxic unsaturated electrophilic compounds commonly target the ubiquitin proteasome system
Insight
  • Industry trends
CDMO trends: Drug development and industry consolidation